Muraymycin nucleoside-peptide antibiotics: uridine-derived natural products as lead structures for the development of novel antibacterial agents

Scholarly Works

• Lee, J.; Hwang, J.-Y.; Oh, D.; Oh, D.-C.; Park, H.-G.; Shin, J.; Oh, K.-B. Tunicamycins from Marine-Derived Streptomyces bacillaris Inhibit MurNAc-Pentapeptide Translocase in Staphylococcus aureus. Marine drugs 2024, 22, 293. doi:10.3390/md22070293
• Kawsar, S. M. A.; Hossain, M. A.; Saha, S.; Abdallah, E. M.; Bhat, A. R.; Ahmed, S.; Jamalis, J.; Ozeki, Y. Nucleoside‐Based Drug Target with General Antimicrobial Screening and Specific Computational Studies against SARS‐CoV‐2 Main Protease. ChemistrySelect 2024, 9. doi:10.1002/slct.202304774
• Astani, E. K.; Malek Zadeh, S.; Sardari, S.; Khosravian, M. DFT QM/MM MD Calculations to Identify Intermolecular Interactions within the Active Sites of MraYAA Bound to Antibiotics Capuramycin, Carbacaprazamycin, and 3′‐Hydroxymureidomycin A. ChemistrySelect 2023, 8. doi:10.1002/slct.202302657
• Li, X.; Ju, J. Intracellularly driven chemical modifications of antimicrobial secondary metabolites: Potent mechanisms of self-resistance. Pharmaceutical Science Advances 2023, 2, 100032. doi:10.1016/j.pscia.2023.100032
• Kumar, G.; Engle, K. Natural products acting against S. aureus through membrane and cell wall disruption. Natural product reports 2023, 40, 1608–1646. doi:10.1039/d2np00084a
• Manning, D.; Huang, T.-Y.; Berida, T.; Roy, S. The challenges and opportunities of developing small molecule inhibitors of MraY. Annual reports in medicinal chemistry 2023, 60, 1–27. doi:10.1016/bs.armc.2023.09.005
• Thilmont, L.; Rosinus, S.; Lutz, M.; Rohrbacher, C.; Ducho, C. Nucleoside-derived inhibitors of MraY: Medicinal chemistry with natural products. New Approaches Towards Novel Antibacterial Agents; Elsevier, 2023; pp 29–85. doi:10.1016/bs.armc.2023.09.001
• Rohrbacher, C.; Zscherp, R.; Weck, S. C.; Klahn, P.; Ducho, C. Synthesis of an Antimicrobial Enterobactin-Muraymycin Conjugate for Improved Activity Against Gram-Negative Bacteria. Chemistry (Weinheim an der Bergstrasse, Germany) 2022, 29, e202202408. doi:10.1002/chem.202202408
• Wan, H.; Ben Othman, R.; Le Corre, L.; Poinsot, M.; Oliver, M.; Amoroso, A.; Joris, B.; Touzé, T.; Auger, R.; Calvet-Vitale, S.; Bosco, M.; Gravier-Pelletier, C. New MraYAA Inhibitors with an Aminoribosyl Uridine Structure and an Oxadiazole. Antibiotics (Basel, Switzerland) 2022, 11, 1189. doi:10.3390/antibiotics11091189
• Singla, R. K.; Dhir, V.; Madaan, R.; Kumar, D.; Singh Bola, S.; Bansal, M.; Kumar, S.; Dubey, A. K.; Singla, S.; Shen, B. The Genus Alternanthera: Phytochemical and Ethnopharmacological Perspectives. Frontiers in pharmacology 2022, 13, 769111. doi:10.3389/fphar.2022.769111
• Arbour, C. A.; Imperiali, B. Backbone-Anchoring, Solid-Phase Synthesis Strategy To Access a Library of Peptidouridine-Containing Small Molecules. Organic letters 2022, 24, 2170–2174. doi:10.1021/acs.orglett.2c00462
• Oliver, M.; Le Corre, L.; Poinsot, M.; Bosco, M.; Wan, H.; Amoroso, A.; Joris, B.; Bouhss, A.; Calvet-Vitale, S.; Gravier-Pelletier, C. A Sub-Micromolar MraYAA Inhibitor with an Aminoribosyl Uridine Structure and a (S,S)-Tartaric Diamide: Synthesis, Biological Evaluation and Molecular Modeling. Molecules (Basel, Switzerland) 2022, 27, 1769. doi:10.3390/molecules27061769
• Shao, X.; Zheng, C.; Xu, P.; Shiraishi, T.; Kuzuyama, T.; Molinaro, A.; Silipo, A.; Yu, B. Total Synthesis and Stereochemistry Assignment of Nucleoside Antibiotic A-94964. Angewandte Chemie (International ed. in English) 2022, 61, e202200818. doi:10.1002/anie.202200818
• Shao, X.; Zheng, C.; Xu, P.; Shiraishi, T.; Kuzuyama, T.; Molinaro, A.; Silipo, A.; Yu, B. Total Synthesis and Stereochemistry Assignment of Nucleoside Antibiotic A‐94964. Angewandte Chemie 2022, 134. doi:10.1002/ange.202200818
• Remennikov, G. Y. Synthesis of pyrimidine-containing alkaloids. The Alkaloids. Chemistry and biology 2022, 88, 49–367. doi:10.1016/bs.alkal.2021.11.001
• Guo, Z.; Tang, Y.; Tang, W.; Chen, Y. Heptose-containing bacterial natural products: structures, bioactivities, and biosyntheses. Natural product reports 2021, 38, 1887–1909. doi:10.1039/d0np00075b
• Oliver, M.; Le Corre, L.; Poinsot, M.; Corio, A.; Madegard, L.; Bosco, M.; Amoroso, A. M.; Joris, B.; Auger, R.; Touzé, T.; Bouhss, A.; Calvet-Vitale, S.; Gravier-Pelletier, C. Synthesis, biological evaluation and molecular modeling of urea-containing MraY inhibitors. Organic & biomolecular chemistry 2021, 19, 5844–5866. doi:10.1039/d1ob00710f
• Mitachi, K.; Mingle, D.; Kurosu, M. A Convenient Protecting Group for Uridine Ureido Nitrogen: (4,4′-Bisfluorophenyl)methoxymethyl Group. Synthesis 2021, 53, 2643–2650. doi:10.1055/a-1464-2473
• Ropponen, H.-K.; Richter, R.; Hirsch, A. K. H.; Lehr, C.-M. Mastering the Gram-Negative Bacterial Barrier - Chemical Approaches to Increase Bacterial Bioavailability of Antibiotics. Advanced drug delivery reviews 2021, 172, 339–360. doi:10.1016/j.addr.2021.02.014
• Niro, G.; Weck, S. C.; Ducho, C. Merging Natural Products: Muraymycin-Sansanmycin Hybrid Structures as Novel Scaffolds for Potential Antibacterial Agents. Chemistry (Weinheim an der Bergstrasse, Germany) 2020, 26, 16875–16887. doi:10.1002/chem.202003387

Explore citations to this article at